tm logo
Trademark Search
MODERNA

View On IC.GC.CA

MODERNA
REGISTERED

on 21 Mar 2024

Last Applicant/ Owned by

MODERNATX INC.

325 Binney StreetCambridge MA 02142

US

Serial Number

2041339 filed on 13th May 2020

Registration Number

TMA1225775 registered on 21st Mar 2024

Registration expiry Date

13th May 2030

Correspondent Address

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

CA

K1P5Y6

MODERNA

Trademark usage description

biochemicals, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids for in vivo, ex vivo, on vivo or in vitro scientific resea Read More

Classification Information

Class [001]
Biochemicals, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids for in vivo, ex vivo, on vivo or in vitro scientific research and medical research; biochemicals, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids for use in the manufacture of pharmaceuticals for treating cancers, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious; reagents for testing sterility of pharmaceuticals; diagnostic reagents for medical-scientific or research use; in vitro diagnostic reagents for scientific use and medical-scientific research use; in vitro diagnostic reagents for scientific purposes; chemicals for use in biotherapeutics, and therapeutics product development and manufacturing processes; polypeptide encoding nucleic acids for laboratory use.

Classification kind code

11

Class [005]
Medical, biological and pharmaceutical preparations for scientific, research, medical, or pharmaceutical use, namely, preparations for preventing and treating cancers, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders; ¿ medical, biological and pharmaceutical preparations containing polypeptide encoding nucleic acids for preventing and treating cancers, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and for preventing and treating rare diseases, namely, Cystic fibrosis, Methylmalonic acidemia, Propionic acidemia, Phenylketonuria, Ornithine transcarbamylase deficiency, Maple syrup urine disease, Arginase-1 deficiency, Factor VIII deficiency, Glycogen storage disorder type 1a, Adult-onset type II citrullinemia and Progressive familial intrahepatic cholestasis type; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; medical diagnostic reagents.

Classification kind code

11

Class [042]
Scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars and therapeutics drugs; design, engineering, research, development and testing services in the field of protein-encoding nucleic acids and polypeptide-encoding nucleic acids.

Classification kind code

11

Mark Details

Serial Number

2041339

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 08th Nov 2021		Search Recorded
Submitted for opposition 20
on 08th Nov 2021		Examiner's First Report
Submitted for opposition 223
on 08th Nov 2021		Total Provisional Refusal
Submitted for opposition 256
on 24th May 2021		Notification of Possible Opposition Sent
Submitted for opposition 48
on 18th Sep 2020		Agent Changed
Submitted for opposition 257
on 23rd Jul 2020		Designation Notification - Madrid Protocol
Submitted for opposition 1
on 22nd Jul 2020		Created
Submitted for opposition 31
on 22nd Jul 2020		Formalized
Submitted for opposition 30
on 13th May 2020		Filed
Submitted for opposition 228
on 13th May 2020		International Registration